8-K: Arbutus Swings to Profit on Qilu Deal, Board Changes

Arbutus Biopharma reported a net income of $2.5 million for Q2 2025, driven by deferred revenue recognition, alongside board appointments and updates on its LNP patent litigation.

Summary

• Arbutus Biopharma reported a net income of $2.5 million for the second quarter ended June 30, 2025, a significant improvement from a net loss of $19.8 million in Q2 2024.
• Total revenue for Q2 2025 was $10.7 million, up from $1.7 million in Q2 2024, primarily due to the recognition of previously-deferred revenue following the conclusion of the strategic partnership with Qilu Pharmaceutical for imdusiran in Greater China.
• Research and development expenses decreased by $10.1 million to $5.5 million in Q2 2025, reflecting cost savings from the August 2024 restructuring efforts, including ceasing discovery efforts and discontinuing the IM-PROVE III clinical trial.
• General and administrative expenses also decreased to $3.3 million in Q2 2025 from $7.5 million in Q2 2024, mainly due to reductions in litigation-related legal fees and employee compensation.
• Cash, cash equivalents, and marketable securities stood at $98.1 million as of June 30, 2025, down from $122.6 million at December 31, 2024.
• Anuj Hasija resigned from the Board of Directors effective August 4, 2025, to focus on a new executive role at Vertex, with no disagreements cited.
• Dr. Roger Sawhney was appointed to the Board of Directors and its Audit and Corporate Governance and Nominating Committees, effective August 4, 2025.
• Dr. Harry L.A. Janssen joined the Scientific Advisory Board effective August 1, 2025, enhancing expertise in chronic hepatitis B virus (cHBV) treatment.
• Updates were provided on ongoing patent infringement litigations: the U.S. litigation against Moderna has a jury trial scheduled for March 2026, international lawsuits against Moderna expect first major hearings in H1 2026, and a ruling in the Pfizer/BioNTech claim construction hearing could potentially come in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the swing to net income and significant revenue increase, albeit driven by a one-time event. Strong cost control and strategic board appointments are positives. However, the cash burn continues, and the ongoing, long-term patent litigation introduces significant uncertainty and risk, tempering overall optimism.

Positives

• Achieved net income of $2.5 million in Q2 2025, a substantial turnaround from a net loss of $19.8 million in Q2 2024.
• Reported a significant increase in total revenue to $10.7 million in Q2 2025, primarily due to the recognition of deferred revenue from the Qilu partnership conclusion.
• Successfully reacquired global rights for imdusiran, its lead compound, after concluding the partnership with Qilu Pharmaceutical.
• Demonstrated effective cost control with substantial reductions in both research and development expenses ($10.1 million decrease) and general and administrative expenses ($4.2 million decrease) due to prior restructuring and cost-cutting efforts.
• Strengthened corporate governance and scientific expertise with the appointment of Dr. Roger Sawhney to the Board and Dr. Harry Janssen to the Scientific Advisory Board.
• Maintains a strong financial position with $98.1 million in cash, cash equivalents, and marketable securities as of June 30, 2025.

Negatives

• Cash, cash equivalents, and marketable securities decreased by $24.5 million from December 31, 2024, to June 30, 2025, with $29.1 million used in operating activities during the first six months of 2025.
• The positive financial results for Q2 2025 are significantly influenced by a one-time recognition of previously-deferred revenue, rather than sustained operational growth.
• Ongoing patent litigation against Moderna and Pfizer/BioNTech continues to incur legal fees, although reduced, and represents a long-term, uncertain process with key hearings and trials extending into 2026.

Risks

• Ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated, may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate.
• The company may elect to change its strategy regarding its product candidates and clinical development activities.
• The company may not receive the necessary regulatory approvals for the clinical development of its product candidates.
• Uncertainties are associated with litigation generally and patent litigation specifically.
• Economic and market conditions may worsen, potentially impacting operations and financial performance.
• Market shifts may require a change in strategic focus, potentially disrupting current plans.
• The workforce reduction and plans to reduce net cash burn may not materially extend the cash runway and may create distraction or uncertainty that could adversely affect operating results, business, or investor perceptions.
• Risks related to the sufficiency of cash resources for foreseeable and unforeseeable operating expenses and capital expenditures.

Future Outlook

The company anticipates continued progress in its chronic hepatitis B virus (cHBV) programs, including the clinical development of imdusiran and AB-101. Key milestones for the ongoing patent litigation include the summary judgment phase for the Moderna U.S. litigation beginning in July 2025, a jury trial scheduled for March 2026, and the first major hearings for international lawsuits against Moderna expected in the first half of calendar year 2026. A ruling in the Pfizer/BioNTech claim construction hearing could potentially come in 2025. All remaining restructuring-related payments are expected to be made in the second half of 2025.

Management Comments

• "We delivered a strong quarter, marked by positive quarterly earnings resulting from the conclusion of our Greater China partnership with Qilu."
• "Once again holding global rights for imdusiran, and launching a late-stage clinically focused Scientific Advisory Board, were two important steps taken this quarter in our quest to drive long-term value through our chronic hepatitis B virus (cHBV) programs."
• "I am excited to announce that Dr. Harry Janssen of Erasmus MC in Rotterdam has joined our Scientific Advisory Board, bringing his unparalleled knowledge and experience in late-stage clinical trials in cHBV."
• "We are also excited to welcome Dr. Roger Sawhney as the newest member of our Board. Dr. Sawhney has enjoyed a distinguished career spanning senior executive roles in biotech, pharma and investing, and also brings extensive public company board experience."
• The company, together with Genevant Sciences, is seeking fair compensation for Moderna's and Pfizer/BioNTech's use of Arbutus's patented LNP technology, without which their COVID-19 vaccines would not have been successful.

Industry Context

Arbutus Biopharma operates in the highly competitive clinical-stage biopharmaceutical sector, specifically targeting infectious diseases like chronic Hepatitis B (cHBV), which represents a significant global unmet medical need with over 250 million people affected worldwide. The company's focus on RNAi therapeutics and oral PD-L1 inhibitors aligns with current trends in developing novel mechanisms for viral control and immune modulation. The ongoing patent litigation against major pharmaceutical companies like Moderna and Pfizer/BioNTech highlights the critical importance of intellectual property in the biotechnology industry, particularly concerning lipid nanoparticle (LNP) delivery technology, which has become foundational for mRNA vaccines. This litigation could set precedents for LNP technology licensing and compensation across the industry.

Comparison to Industry Standards

• The company's lead compound, imdusiran, has shown promising early clinical data, with 8 patients achieving a functional cure in combination therapy. This is a significant outcome in the cHBV space, where functional cures are the ultimate goal and are rarely achieved with current standard-of-care nucleos(t)ide analog (NA) therapy alone. For comparison, companies like Gilead Sciences and Johnson & Johnson also have cHBV programs, but functional cure rates remain a high bar across the industry.
• The LNP technology at the center of the litigation is foundational to successful mRNA vaccines, similar to those developed by Moderna and BioNTech/Pfizer. The company's pursuit of fair compensation for its patented LNP technology reflects a broader industry trend where intellectual property rights for platform technologies are fiercely defended, as seen in other patent disputes involving foundational drug delivery or gene editing technologies.

Management Changes

Corporate Governance

Legal Proceedings

• U.S. patent infringement litigation against Moderna, Inc. and a Moderna affiliate: Fact discovery completed, expert discovery concluding. Summary judgment phase began in July 2025. Jury trial scheduled for March 2026. Case reassigned to a different judge in July 2025.
• Five international patent infringement lawsuits filed against Moderna and/or its affiliates in March 2025: Seeking to enforce patents protecting the company's LNP technology across 30 countries. First major hearings expected in the first half of calendar year 2026.
• Patent infringement litigation against Pfizer Inc. and BioNTech SE: Claim construction hearing occurred in December 2024. The court has not provided guidance for the timing of its ruling, but such ruling could potentially come in 2025.

Stakeholder Impact

• **Shareholders**: The swing to net income and increased revenue, albeit from a one-time event, may be viewed positively, indicating financial stabilization and effective cost management. The reacquisition of global rights for imdusiran could enhance future value. However, the ongoing litigation introduces long-term uncertainty and potential for significant financial outcomes (positive or negative).
• **Employees**: The prior workforce reduction in August 2024 has led to reduced operating expenses, but also implies a leaner organization. The focus on clinical development of imdusiran and AB-101 provides clear strategic direction for remaining staff.
• **Customers/Patients**: Continued development of imdusiran and AB-101 offers potential new treatment options for chronic Hepatitis B, addressing a significant unmet medical need.
• **Creditors**: The strong cash position of $98.1 million provides financial stability, reducing immediate concerns about liquidity, despite the cash burn from operating activities.
• **Partners (Genevant Sciences)**: The company continues to consult closely with and support Genevant Sciences in protecting and defending its intellectual property in the ongoing LNP litigation, indicating a strong collaborative effort.

Next Steps

• Continue advancing the clinical development of imdusiran and AB-101 for cHBV infection.
• Proceed with the summary judgment phase of the U.S. litigation against Moderna, which began in July 2025.
• Prepare for the jury trial in the Moderna U.S. litigation scheduled for March 2026.
• Anticipate the first major hearings in the five international lawsuits against Moderna in the first half of calendar year 2026.
• Await the court's ruling in the Pfizer/BioNTech claim construction hearing, which could potentially come in 2025.
• Make all remaining restructuring-related payments in the second half of 2025.

Key Dates

Recommendation

The company's Q2 2025 results show a positive shift to net income and a significant revenue increase, primarily driven by a one-time deferred revenue recognition and substantial cost reductions from prior restructuring. While these indicate improved financial discipline and a stronger balance sheet, the core business remains in clinical development with a continued cash burn from operations. The ongoing, complex, and long-term patent litigation against Moderna and Pfizer/BioNTech represents both a significant potential upside (if successful) and a substantial risk (due to legal costs and uncertainty). Given the mix of one-time financial gains, ongoing operational burn, and the high-stakes, protracted legal battles, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials and key developments in the patent litigation for future re-evaluation.

Keywords

Biopharma, Hepatitis B, HBV, RNAi therapeutic, Imdusiran, AB-729, AB-101, LNP technology, Patent litigation, Moderna lawsuit, Pfizer BioNTech lawsuit, Clinical stage, Financial results, Board of Directors, Corporate governance, Infectious disease